MTX 101 - Mozart Therapeutics
Alternative Names: MTX-101 - Mozart TherapeuticsLatest Information Update: 13 Nov 2024
Price :
$50 *
At a glance
- Originator Mozart Therapeutics
- Class Antihyperglycaemics; Bispecific antibodies
- Mechanism of Action CD8 antigen inhibitors; KIR receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Coeliac disease; Type 1 diabetes mellitus
Most Recent Events
- 07 Nov 2024 Pharmacodynamics data from preclinical studies in Autoimmune disorders released by Mozart Therapeutics
- 05 Nov 2024 Pharmacodynamics data from a preclinical study in Type 1 diabetes mellitus released by Mozart Therapeutics
- 17 Jun 2024 Phase-I clinical trials in Coeliac disease in Australia (IV) (NCT06324604)